Product Quality Review programme formalised
Ergopharm has formalised a Product Quality Review (PQR) programme across its registered products, establishing a fixed annual cycle in which each product's manufacturing and quality data are reviewed together to confirm that processes remain consistent and that the registered specifications remain appropriate.
Until now, product data at the Ergopharm Advanced Research Centre in Vadodara were examined as part of routine batch release and periodic trending, but without a single standardised report drawing the picture together for each product over a defined period. The formalised PQR programme closes that gap. Under a governing standard operating procedure, every product on the register now receives a written annual review that consolidates the year's batch records, in-process and finished-product test results, deviations, out-of-specification investigations, changes and stability data into one document with defined authorship, review and approval.
“Reviewing each product's full year in one place turns scattered data into a documented basis for continued confidence in the process.”
The programme is built around the review disciplines described in ICH Q10, the Pharmaceutical Quality System guideline reached at Step 4 in June 2008. Q10 sets out process performance and product-quality monitoring, corrective and preventive action (CAPA), change management and management review as the four working elements of a quality system, and the PQR is the periodic instrument that draws those threads together for each product. Each review examines batch-to-batch consistency, the effectiveness of CAPAs raised during the period, the status of changes made under change control, and any trends in stability results held under the ICH Q1A(R2) storage conditions.
In practice, the review looks for signals rather than isolated events: recurring deviations, drift in a critical quality attribute, dissolution or assay results creeping toward a limit, or a cluster of complaints pointing at a single process step. Sterile injectables and oral solids each receive their own review, so that findings specific to aseptic processing or to solid-dose manufacture are not diluted in an aggregate view. The programme also cross-checks that the specifications and analytical methods applied through the year remain the currently approved versions.
Where a review identifies an adverse trend or a specification that no longer reflects manufacturing reality, the finding is fed back through CAPA and change control, and material conclusions are escalated to management review. In this way the PQR is not a paperwork exercise but a scheduled feedback loop: it gives the Qualified Person releasing batches a documented, year-on-year basis for continued confidence, and it strengthens traceability by tying each product's history to a single retrievable record.
Key facts
- Programme
- Annual Product Quality Review for every registered product
- Standard
- Aligned to ICH Q10 (Pharmaceutical Quality System, Step 4, Jun 2008)
- Scope reviewed
- Batch records, test results, deviations, OOS, changes and stability data
- Governance
- Findings routed via CAPA and change control; escalated to management review